ArticleBMC pulmonary medicine2022

EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.

Zhenxiang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.